Investor Presentation

TML/BSE/NSE/2026-27/19 13th August, 2026 Corporate Relationship Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Dalal Street, Mumbai- 400001 Bandra Kurla Complex, Scrip Code – 530199 Bandra (East), Mumbai- 400051 Symbol: THEMISMED Dear Sir / Madam, Subject: Investor Presentation In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors’ Presentation of the Company, with respect to Business Overview of Themis Medicare Limited (‘the Company’) for the quarter ended 30th June, 2026. Further, a copy of the same is also available on the website of the Company, viz., https://www.themismedicare.com Kindly take the same on record and acknowledge receipt of the same. Thanking you, Yours faithfully, For Themis Medicare Limited Dr. Dinesh S. Patel Director Themis Medicare Limited Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India *Tel.: 91-22-67607080*Fax: 91-22-67607070/ 28746621 Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat CIN No.: L24110GJ1969PLC001590 *Tel/ Fax No.: Regd. Off.: 0260-2431447/ 2430219 *E-mail: themis@themismedicare.com*Website: www.themismedicare.com In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Result Update Presentation Q1 FY27 Disclaimer This presentation has beenprepared by ThemisMedicare Limited(the “Company” or “Themis” or“TML”)solely for informationpurposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offeringdocument containing detailedinformationabout theCompany. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makesnorepresentationorwarranty,expressorimplied.ThisPresentationmaynotbeallinclusiveandmaynotcontainalloftheinformationthat youmayconsidermaterial.Anyliability inrespectofthecontents of,oranyomissionfrom,this Presentationisexpresslyexcluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limitedto, the performance ofthe Indianeconomy andofthe economies ofvarious international markets, the performance of the industryinIndia and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposuretomarketrisks,aswellasotherrisks.TheCompany’sactualresults,levelsofactivity,performanceorachievementscoulddiffermaterially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking informationcontainedinthisPresentation.Any forward-lookingstatementsandprojections made bythird parties includedinthis Presentationare notadoptedbytheCompany andtheCompany isnotresponsible forsuchthirdpartystatements andprojections. Table of Contents Consolidated FinancialHighlights Company Overview Way Ahead Management Comment Commentingontheresult,Dr.SachinPatel,ManagingDirector&CEO,said: “The Company continued to navigate market headwinds through the first quarter of this fiscal. Consolidated revenue forQ1 FY27 stood at ₹86.96 crore. The Company reported a strong improvement in bottom-line performance, with Profit Before Tax (PBT) at ₹38.6 crore compared with a loss of ₹14.1 crore in Q1 FY26.PAT stood at ₹24.6 crore predominantly contributed by one off gains, translating into a healthy PAT margin of 28.3%, compared with a loss of ₹14.2 crore in the corresponding quarter last year. The Company continues to focusonstrengthening profitability anddrivingsustainable growthacrossitsbusiness segments. During the quarter, Critical care business registered growth driven by focused brand promotion. The API and institution business look promisingwith visibility ofhealthy recovery inthis financial year.We continue toprioritize cash flow throughfastercollections, recovery oflong-pending receivables,optimization ofworkingcapital, andoverallcostefficiencies. R&D investments were around 8% of revenue, reflecting the Company’s commitment towards developing differentiated products and strengthening itslong-termpipelineacrosskeytherapeutic areas. Going forward, management remains optimistic on improving business momentum supported by operational efficiencies, stronger productivity measures,costoptimization initiatives, andgradual recoveryincorebusiness segments.” Consolidated Financial Highlights Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 10.9% 22 4.9% 97.6 12 90.1 87.0 -10.1 -3.1 9.8 78.0 76.5 2 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 -4.0% -10.3% -28 -52.4 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 -58 -60.3% PAT (Rs. Cr.) / Margin (%) EPS (Rs.) 28.3% 2.67 11.2% 11.6% 24.6 1.10 -14.2 -3.6 10.1 8.9 0.96 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 -4.6% Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 -14.6% -0.39 -1.54 *Revenue consists of Other Operating Revenue **EBITDA is excl. Other Income Consolidated Quarterly Financial Highlights – Q1 FY27 Particulars (Rs.Cr.) Q1FY27 Q1FY26 Y-o-Y(%) Q4FY26 Net Revenue 86.96 97.58 (10.9%) 76.53 Costof MaterialConsumed 17.63 12.43 14.27 PurchaseofSIT 49.81 21.68 11.46 Changes inInventory (9.46) 18.29 (1.98) • Headwinds in API Employee Expenses 22.18 24.85 21.06 business caused OtherExpenses 59.21 30.41 27.96 TotalExpenditure 139.38 107.66 29.5% 72.77 contraction in top line EBITDA (52.42) (10.08) (420.0%) 3.76 EBITDAMargin (60.28%) (10.33%) (4,995 bps) 4.92% OtherIncome 0.99 1.18 3.67 • Price adjustment in Depreciation 2.54 2.55 2.60 inventory & certain Interest/ Finance Cost 2.98 2.47 2.70 one-off expenses ShareofP/Lof Associates &JV 2.59 (0.14) 6.93 hampered margins Impactof Labour Cost 0.00 0.00 0.00 Profit on Sale of Shares 92.95 0.00 0.00 PBT 38.60 (14.06) 9.06 Tax 13.99 0.16 0.17 PAT 24.61 (14.22) 273.1% 8.89 PATMargin% 28.30% (14.57%) 4,287 bps 11.61% Basic EPSin Rs. 2.67 (1.54) 0.96 Consolidated Financial Highlights – FY26 Particulars (Rs.Cr.) FY26 FY25 Y-o-Y (%) Net Revenue 342.24 405.51 (15.6%) Costof MaterialConsumed 57.30 76.31 PurchaseofSIT 63.00 73.67 Changes inInventory 9.17 (17.98) Employee Expenses 93.52 96.38 (3.0%) OtherExpenses 118.85 128.10 TotalExpenditure 341.84 356.46 (4.1%) EBITDA 0.39 49.05 (99.2%) EBITDAMargin 0.11% 12.10% OtherIncome 9.36 4.67 Depreciation 10.32 9.93 Interest/ Finance Cost 10.69 10.04 ShareofP/Lof Associates &JV 14.05 5.93 Impactof Labour Cost (0.87) 0.00 PBT 1.93 39.67 (95.1%) Tax 0.78 9.84 PAT 1.14 29.83 (96.2%) PATMargin% 0.33% 7.36% EPSin Rs. 0.12 3.24 (96.3%) Consolidated Balance Sheet as on 31st Mar’26 Ason 31st Ason 31st Ason 31st Ason 31st Equity & Liabilities Assets Mar’26 Mar’25 Mar’26 Mar’25 Shareholders Funds 398.58 402.60 Non Current Assets 292.93 284.17 Share Capital 9.21 9.20 Plant, Property & Equipment 166.40 172.03 Other Equity 389.37 393.39 Capital Work In Progress 2.47 2.51 Non Controlling interest 0.00 (0.00) Right-of-use Assets 0.00 0.00 Non Current Liabilities 33.17 29.31 Intangible Assets 0.12 0.33 Long Term Borrowing 21.86 18.61 Investments 108.50 94.45 Lease Liabilities 0.00 0.00 Financial Assets LT Provisions 1.94 1.87 Investments 0.34 0.32 D [Showing first 8,000 characters — download PDF for full document]